To market over-the-counter (OTC) drugs in China, stakeholders used to obey the same documentation requirements and marketing authorization application procedures as prescription drugs. In recent years, cross-border e-commerce has been developing as a different approach to enter China's OTC drug market. Cross-border e-commerce (CBEC) refers to selling goods on a third-party online CBEC platform from one country to individual consumers in another country. This article introduces -China's OTC Drug Market Overview -Differences Between CBEC and General Trade -CBEC Positive List -Three Delivery Modes for CBEC -Two Regional OTC Drug CBEC Pilot Programs in Beijing and Henan -How to Establish an Online Drugstore on a Chinese CBEC Platform -BaiPharm's CBEC Service for Overseas Medical Suppliers https://baipharm.chemlinked.com/insights/how-to-sell-otc-drugs-to-china-through-cross-border-e-commerce

In June 2023, China NMPA approved 33 new drugs, among which 26 are chemical drugs and 7 are biological products. 1. eVENUS Pharma’s Oteseconazole Capsules (class 1 innovative drug) 2. XZenith Biopharm’s Anaprazole Sodium Enteric-coated Tablets (class 1 innovative drug) 3. Betta Pharma’s Vorolanib Tablets (class 1 innovative drug) 4. Jiangsu Hengrui Pharma’s Retagliptin Phosphate Tablets (class 1 innovative drug) 5. Jiangsu Hansoh Pharma’s Pegmolesatide Injection (class 1 innovative drug) 6. Qilu Pharma’s Iruplinalkib Tablets (class 1 innovative drug) 7. Jiangsu Hengrui Pharma’s Dalpiciclib Isethionate Tablets 8. Immedica Pharma’s Glycerol Phenylbutyrate Oral Liquid 9. Menarini’s Bilastine Tablets 10. Teva Pharmaceutical’s Glatiramer Acetate Injection 11. AstraZeneca’s Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets 12. Neurelis’ Diazepam Nasal Spray 13. Fresenius Kabi’s Compound Amino Acid (16AA), Glucose (12.6%) and Electrolyte Injection 14. Recordati Rare Diseases’ Carglumic Acid Dispersible Tablets 15. Shionogi’s Lusutrombopag Tablets 16. Genentech’s Pralsetinib Capsules 17. Ipsen Pharma’s Triptorelin Pamoate for Injection 18. Kelun Industry Group’s ω-3 Fish Oil Medium and Long Chain Fat Emulsion / Amino Acid (16) / Glucose (36%) Injection (first generic) 19. Jincheng Jinsu Pharma’s Amisulpride Oral Solution (first generic) 20. Yangtze River Pharma’s Amlodipine Besilate and Benazepril Hydrochloride Capsules (first generic) 21. Shenzhen Salubris Pharma’s Enarodustat Tablets (first generic) 22. CP Pharma Qingdao’s Calcitriol Oral Solution (first generic) 23. NJCTTQ’s Lubiprostone Soft Capsules (first generic) 24. Hefei Yifan Pharma’s Clofarabine Injection (first generic) 25. Jewim Pharma’s Minoxidil Topical Solution (first generic) ... https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-june-2023

BaiPharm offers a full portfolio of #China NMPA #compliance consulting services alongside marketing solutions, especially for e-commerce channels. We ensure professional response and full support to clients, backed by our senior expert team. ✅ Drug Application ✅ E-commerce Solutions ✅ #Pharmacovigilance ✅ #Consulting and Training ✅ Local Agency Support ... More details of our service at https://baipharm.chemlinked.com/service/compliance

On Jul. 2, 2020, the National Medical Product Administration (#NMPA) and the National Health Commission (NHC) published the 2020 Edition of the #Pharmacopoeia of the People's Republic of #China, which came into force on Dec. 30, 2020. All finished pharmaceutical products with China's #marketing authorization shall meet the technical requirements of dosage forms, test methods, guidelines, etc., in the Chinese Pharmacopoeia since Dec. 30, 2020. Chinese Pharmacopoeia 2020 English Version has been available since Mar. 14, 2023. Contact📞 BaiPharm if you'd like to get access to the English version. https://baipharm.chemlinked.com/news/china-issued-the-2020-edition-of-chinese-pharmacopoeia